You are here
SBIR Phase I: Developing a Rapid Antibody Generation Platform for Emerging COVID-19 Variants
Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 2033772
Agency Tracking Number: 2033772
Amount:
$256,000.00
Phase:
Phase I
Program:
SBIR
Solicitation Topic Code:
BT
Solicitation Number:
N/A
Timeline
Solicitation Year:
2020
Award Year:
2020
Award Start Date (Proposal Award Date):
2020-09-01
Award End Date (Contract End Date):
2021-08-31
Small Business Information
4000 Mason Road
Fluke Hall, Suite 304
Seattle, WA
98195
United States
DUNS:
080919240
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: Randolph Lopez Barrezueta
Phone: (858) 405-7116
Email: rlopez@aalphabio.com
Phone: (858) 405-7116
Email: rlopez@aalphabio.com
Business Contact
Name: Randolph Lopez Barrezueta
Phone: (858) 405-7116
Email: rlopez@aalphabio.com
Phone: (858) 405-7116
Email: rlopez@aalphabio.com
Research Institution
N/A
Abstract
The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to improve and accelerate the development of antibody therapies to fight the COVID-19 pandemic. Antibody therapies are in development to target SARS-CoV-2, the virus r
* Information listed above is at the time of submission. *
